SOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 12,232 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 12,232 shares of the company’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.72, for a total transaction of $57,735.04. Following the sale, the chief executive officer owned 3,711,968 shares in the company, valued at $17,520,488.96. This represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,939.24.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Stock Up 2.3%

Shares of NASDAQ SOPH opened at $4.96 on Wednesday. The firm’s 50-day moving average price is $4.74 and its 200-day moving average price is $4.72. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.04. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The business had revenue of $21.71 million for the quarter, compared to analysts’ expectations of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. On average, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Aggregate insider activity: company executives and other insiders sold a combined ~43,400 shares across transactions on April 10 and April 13. Sales were executed under pre-arranged Rule 10b5-1 plans and were reported in SEC Form 4 filings. SEC Form 4
• Neutral Sentiment: CEO Jurgi Camblong sold 12,232 shares on April 10 and 4,399 shares on April 13 (total ~16,631 shares). Trades were made under a 10b5-1 plan to cover tax withholding tied to equity vesting; his remaining direct stake remains large (>3.7M shares). SEC Form 4
• Neutral Sentiment: President Ross Muken sold 3,687 shares on April 10 and 4,442 shares on April 13 (~8,129 shares). Transactions were under a 10b5-1 plan and described as tax-related for vested awards. SEC Form 4
• Neutral Sentiment: Other insiders (Philippe Menu and Zhenyu Xu) each made paired sales on April 10 and April 13 totaling ~8,125 and ~8,120 shares respectively; Well Daan Van sold 2,400 shares on April 10. All trades were 10b5-1, tax-withholding sales. SEC Form 4 (Menu) SEC Form 4 (Xu) SEC Form 4 (Van)

Analyst Upgrades and Downgrades

SOPH has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Finally, Guggenheim upped their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds have recently added to or reduced their stakes in the company. Green Alpha Advisors LLC grew its stake in SOPHiA GENETICS by 10.8% in the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after acquiring an additional 4,444 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares in the last quarter. Savvy Advisors Inc. bought a new position in SOPHiA GENETICS in the 3rd quarter worth about $48,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS in the 3rd quarter worth about $49,000. Finally, Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS in the 4th quarter worth about $49,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.